PDC and anemia: In line, PHD inhibitors, targeting all three isoforms to alleviate anemia in chronic kidney disease, also ameliorated lipid metabolism in mice and humans, and atherogenesis in mice (Rahtu-Korpela et al., 2016; Chen et al., 2019a, b).